CVR 37211265Entrepreneurial company (IVS)Forskning og eksperimentel udvikling indenfor bioteknologi (721100)København ØFounded 8 Nov 2015
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about TychoBio IVS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
0
CVR, 2018
Revenue
0
DKK, annual report 2020
Result
-2.4K
DKK, annual report 2020
Equity
1.4K
DKK, annual report 2020
Steglich-Andersen Ventures IVSCVR 39049724, 25% to under 33.3% of capital and votes, until 13 Apr 2023
Jacob Iver Steglich-Willertuntil 25 Jan 2022
Victor Formanuntil 25 Jan 2022
No current owner is registered.
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
33.3% to under 50% of capital and votesnotified 1 Nov 20178 Nov 2015 to 1 Nov 2017
33.3% to under 50% of capital and votes8 Nov 2015 to 1 Nov 2017
33.3% to under 50% of capital and votes8 Nov 2015 to 1 Nov 2017
CVR 3904972425% to under 33.3% of capital and votes1 Nov 2017 to 13 Apr 2023
CVR 3904974025% to under 33.3% of capital and votesnotified 1 Aug 20181 Nov 2017 to 1 Aug 2018
CVR 3904976750% to under 66.7% of capital and votesnotified 1 Aug 20181 Nov 2017 to 30 Sep 2021
CVR 3905218010% to under 15% of capital and votes1 Nov 2017 to 31 Mar 2020
Decided by Dandex with fixed rules from CVR and the filed annual reports, and for the auditor's report, the business model and the revenue model a calibrated decision model reading the report's text and the purpose clause, not registered by the company. Each label links to its definition.
CVR lists no current officers for this company.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
8 Nov 2015 to 16 Nov 2026.
Q4 2018, quarterly: 0 employees, 0 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Oct 2017 | Jan 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Q4 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Employees | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| FTE | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Quarterly |
The legal entity's own headcount as CVR records it, not the annual report's average, which may cover a group. Quarterly Q4 2018; monthly Oct 2017 to Aug 2018.
Latest Q4 2018, published 26 Jun 2019. Source: CVR employment series (Årsbeskæftigelse, Kvartalsbeskæftigelse, Månedsbeskæftigelse).
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenue | Not reported | 0 | 0 | Not reported | 0 |
| Gross profit | 46 | Not reported | Not reported | Not reported | Not reported |
| Operating profit | Not reported | -178 | -272 | -11 | -2 |
| Result for the year | +36 | -30 | +19 | -4 | -2 |
| Equity | 36 | 6 | 16 | 12 | 1 |
| Total assets | 50 | 8 | 16 | 12 | 1 |
| Credit metrics (Dandex calculations) | |||||
| Revenue growth (omsætningsvækst) | Not reportednote 1 | -100% | n.m.note 2 | Not reportednote 3 | Not reportednote 3 |
| EBITDA | Not reportednote 4 | -178 | Not reportednote 4 | Not reportednote 4 | Not reportednote 4 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
DKK thousands. Annual reports via XBRL. Not every period is a full year: 2019 covers 14 months (1 Nov 2018 to 31 Dec 2019). Changes against it compare periods of different length.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages. Gearing and interest coverage are multiples. Rows marked Pro hold a value in the Pro plan. Definitions.
Annual report 2020
1 Jan 2020 to 31 Dec 2020, published 31 Jan 2021
Annual report 2019
1 Nov 2018 to 31 Dec 2019, published 24 Aug 2020
Annual report 2018
1 Nov 2017 to 31 Oct 2018, published 8 Apr 2019
Annual report 2017
1 Nov 2016 to 31 Oct 2017, published 28 Feb 2018
Annual report 2016
8 Nov 2015 to 31 Oct 2016, published 11 Jul 2017
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The rows marked Pro on this page hold values in the Pro plan. For TychoBio IVS, that is:
Have Pro? Sign in to see the values on this page.
Each registered value from the day it took effect, newest first.
From CVR, read 16 Nov 2026. Text such as the signing rule and purpose is shown as registered.
From CVR, read 16 Nov 2026. A change is counted each time the registry records a new value, so a corrected address or an audit firm under a new entity counts too.
13 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Konkursbehandlingen afsluttet 13.04.2023, virksomheden opløst
Konkursdekret afsagt 18.05.2022 af Sø- og Handelsrettens Skifteretsafdeling
Likvidatorer:
Fratrådte:
Marianne Philip, den 18.05.2022.
Revision:
Likvidatorer:
Tiltrådte:
Sø- og Handelsrettens Skifteretsafdeling har udnævnt følgende likvidatorer: Marianne Philip, 2100 København Ø, den 22.02.2022.
Virksomheden tegnes af en likvidator
Virksomhedens kreditorer opfordres til at anmelde deres krav til likvidator. Krav skal anmeldes senest tre måneder fra dags dato.
Anmodning om opløsning, jf. selskabslovens § 225 sendt til Sø- og Handelsrettens Skifteretsafdeling den 25.01.2022
Direktion:
Fratrådte:
Victor Forman, den 25.01.2022, Jacob Iver Steglich-Willert, den 25.01.2022.
Ny adresse: c/o Jacob Steglich-Andersen, H.P. Ørums Gade 23, st., 2100 København Ø
Vedtægter ændret: 06.04.2019
Regnskabsår ændret til: 01.01 - 31.12
Omlægningsperiode: 01.11.2018 - 31.12.2019
Vedtægter ændret: 01.08.2018
Ny adresse: Sandbjerggade 44, 3. tv, 2200 København N
Ny kommune: København
Direktion:
Fratrådte:
Josephine Schrøder (adm. dir), den 01.08.2018.
Selskabet tegnes af de to direktører.
Ny adresse: c/o Center for Synthetic Biology, Thorvaldsensvej 40, 1., 1871 Frederiksberg C
Ny kommune: Frederiksberg
Direktion:
Fratrådte:
Josephine Schrøder, den 01.03.2018, Jacob Iver Steglich-Andersen (adm. dir), den 01.03.2018.
Tiltrådte:
Josephine Schrøder (adm. dir), den 01.03.2018, Jacob Iver Steglich-Andersen, den 01.03.2018.
Vedtægter ændret: 07.11.2017
Selskabet tegnes af den administrerende direktør eller af to medlemmer af direktionen i forening..
Direktion:
Fratrådte:
Charles William Comstive Wright, den 01.11.2017.
Tiltrådte:
Jacob Iver Steglich-Andersen (adm. dir), den 01.08.2017.
Den under 03.05.2017 fremsendte anmodning til Sø- og Handelsrettens Skifteretsafdeling om opløsning af virksomheden, er tilbagetaget.
Direktion:
Tiltrådte:
Victor Forman, den 12.06.2017, Josephine Schrøder, den 12.06.2017, Charles William Comstive Wright, den 12.06.2017.
Virksomheden tegnes af direktionen..
Anmodning om opløsning, jf. selskabslovens § 225 sendt til Sø- og Handelsrettens Skifteretsafdeling den 03.05.2017
Direktion:
Fratrådte:
Victor Forman, den 03.05.2017, Josephine Schrøder, den 03.05.2017, Charles William Comstive Wright, den 03.05.2017.
Stiftelsesdato: 08.11.2015.
Seneste vedtægtsdato: 08.11.2015.
Kapital:
kr. 100,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 100,00 til kurs 100,00, fuldt indbetalt.
Stiftere:
Victor Forman, den 08.11.2015, Josephine Schrøder, den 08.11.2015, Charles William Comstive Wright, den 08.11.2015.
Direktion:
Victor Forman, den 08.11.2015, Josephine Schrøder, den 08.11.2015, Charles William Comstive Wright, den 08.11.2015.
Virksomheden tegnes af direktionen.
Første regnskabsår:
08.11.2015 - 31.10.2016.
Regnskabsår:
01.11 - 31.10.
Formål:
Virksomhedens formål er at producere kemikalier i mos
1 registered in CVR.
P-number 1020875743H.P. Ørums Gade 23, 2100 København Ø